C3 and acute myeloid leukemia: In addition, we compared the response status (SD/PD or CR/PR) of immunotherapy for patients with AML among the aggrephagy-related cell clusters (UBE2N+NK-C1, UBE2V1+NK-C2, DYNC1H1+NK-C3, PARK7+NK-C4, TUBA1B+CD8+ T−C1, DYNC1H1+CD8+ T−C2, UBE2V1+CD8+ T−C3, UBE2N+CD8+ T−C4, DYNLL1+Mac-C1, UBE2V1+Mac-C2, TUBA1A+Mac-C3, and PAPK7+Mac-C4) based on public dataset (Figure 7A).